M34.9 Insurance Policy Changes

ICD-10 M34.9 is officially defined as "Systemic sclerosis, unspecified." code M34.9 is referenced in 6 tracked payer policy changes from Excellus BlueCross BlueShield and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code M34.9 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Excellus BlueCross BlueShield · Effective Feb 19, 2026Medium impact
Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) 7.02.02
Excellus medical policy 7.02.02 sets when allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered medically appropriate. It applies when the candidate meets the transplanting institution's selection criteria, the multidisciplinary team evaluates the individual and recommends treatment, and the individual is treated for one of the listed indications. The listed indications include acute and chronic leukemias, non-Hodgkin lymphoma, myelodysplastic diseases at intermediate or high risk, sickle cell anemia under stated criteria, transfusion-dependent thalassemia, bone marrow failure syndromes, severe combined immunodeficiency, hemophagocytic disorders, several storage and leukodystrophy disorders, and certain skeletal and metabolic bone disorders. Allo-HSCT is considered investigational for all other indications. The February 19, 2026 revision simplified the criteria to the indication level, removed the investigational indications list and added HCPCS code S2142.
Aetna · Identified Oct 4, 2026Medium impact
Hematopoietic Cell Transplantation for Autoimmune Diseases and Miscellaneous Indications (CPB 0606, reviewed 2026-09-18)
Aetna considers autologous hematopoietic cell transplantation medically necessary for adults 18 to 69 years old with rapidly progressive scleroderma (systemic sclerosis) at risk of organ failure. This applies when active interstitial lung disease is present with a forced vital capacity or diffusing capacity of the lung for carbon monoxide below 70% of predicted, or when previous scleroderma-related renal disease is present, and the member meets the transplanting institution's selection criteria or, if there are none, has none of the listed exclusion criteria. Aetna considers autologous or allogeneic hematopoietic cell transplantation experimental, investigational, or unproven for conditions including multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, myasthenia gravis, type I diabetes mellitus, age-related macular degeneration, amyotrophic lateral sclerosis, polycythemia vera, and thrombotic thrombocytopenic purpura.
Aetna · Identified Aug 18, 2026Medium impact
Total Body Plethysmography (CPB 0474, reviewed 2026-07-17)
Aetna's Clinical Policy Bulletin 0474 covers total body plethysmography as an adjunct to complete pulmonary function testing, including residual volumes and diffusion, for these indications: determining bronchial hyper-reactivity in response to methacholine, histamine, or isocapnic hyperventilation; determining response to bronchodilators in persons who show a clinical response but no FEV1 improvement by spirometry; evaluating obstructive lung diseases such as bullous emphysema and cystic fibrosis; evaluating airflow resistance in obstructive processes where plethysmography is needed for accurate true lung volumes; measuring lung volumes to distinguish restrictive from obstructive processes when vital capacity is below 80% predicted on spirometry; and measuring lung volumes when multiple repeated trials are required or the subject cannot perform multi-breath tests. The policy considers total body plethysmography experimental, investigational, or unproven for all other indications, including screening asymptomatic persons with chronic obstructive pulmonary disease, pectus excavatum, primary pulmonary hypertension, monitoring bleomycin toxicity, scoliosis, and systemic sclerosis.
Aetna · Identified Aug 17, 2026Medium impact
Hematopoietic Cell Transplantation for Autoimmune Diseases and Miscellaneous Indications (CPB 0606, reviewed 2025-09-10)
Aetna's Clinical Policy Bulletin 0606 covers hematopoietic cell transplantation for autoimmune diseases and other listed conditions. Aetna considers autologous transplant medically necessary for adults aged 18 to 69 with rapidly progressive scleroderma (systemic sclerosis) at risk of organ failure when either active interstitial lung disease with an FVC or DLCO below 70% of predicted is present, or previous scleroderma-related renal disease is present, and the member meets the transplanting institution's selection criteria or, where none exist, has none of the listed exclusion criteria. Aetna considers autologous or allogeneic transplant experimental, investigational or unproven for many autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, type 1 diabetes and myasthenia gravis, and for miscellaneous conditions such as age-related macular degeneration, amyotrophic lateral sclerosis, polycythemia vera and thrombotic thrombocytopenic purpura.
Aetna · Identified Aug 17, 2026Medium impact
ADAMTS13 Assay for Thrombotic Thrombocytopenic Purpura (TTP) (CPB 0780, reviewed 2026-04-27)
Aetna considers the ADAMTS13 assay medically necessary for assessing prognosis in persons with thrombotic thrombocytopenic purpura (TTP), and for distinguishing hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA, also called transplant-associated TMA) from TTP in persons with overlapping features when the test will be used to inform treatment. Aetna considers the assay experimental, investigational, or unproven for the uses it lists because of insufficient evidence, including sepsis-associated thrombotic microangiopathy, hemolytic uremic syndrome, acute myelogenous leukemia, colorectal cancer survival, COVID-19, cerebral infarction, and ADAMTS13 mutation testing for non-cirrhotic portal hypertension.
Aetna · Identified Aug 17, 2026Medium impact
Fetal Echocardiography and Magnetocardiography (CPB 0106, reviewed 2026-03-26)
Aetna considers fetal echocardiograms, Doppler and color flow mapping after 12 weeks gestation medically necessary for listed indications. These include a mother with type 1 diabetes or pregestational type 2 diabetes on insulin during the first trimester, a mother with systemic lupus erythematosus, a fetal nuchal translucency of 3.5 mm or greater in the first trimester, pregnancies conceived by IVF or ICSI, monochorionic twins, suspected twin-twin transfusion syndrome, suspected or documented fetal arrhythmia, suspected or known fetal chromosomal abnormalities, single umbilical artery, persistent right umbilical vein, non-immune fetal hydrops or unexplained severe polyhydramnios, and seizure disorders in members even if they are not taking anti-seizure medication. Fetal exposure to anti-seizure medications, excessive alcohol, lithium, paroxetine or retinoids is also a listed indication. Repeat studies are covered for listed findings and for fetal surveillance of anti-Ro (SSA) or anti-La (SSB) exposure, which may be repeated every 1 to 2 weeks starting at 16 weeks gestation through 28 weeks, then every other week until 32 weeks. Fetal echocardiograms for advanced maternal age screening, gestational diabetes even if requiring insulin after the first trimester, modafinil exposure, selective serotonin reuptake inhibitors except paroxetine, tacrolimus, a tortuous ductus arteriosus, and suspected cystic fibrosis are experimental, investigational or unproven. Fetal magnetocardiography and deep learning-based models for diagnosing fetal arrhythmia are also experimental, investigational or unproven.

Watch M34.9

Get one email when a payer policy names M34.9, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code M34.9?

There are 6 tracked policy changes affecting code M34.9, including updates from Excellus BlueCross BlueShield, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code M34.9?

Payers that have issued tracked updates for code M34.9 include: Excellus BlueCross BlueShield, Aetna.

How do I get notified when code M34.9 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code M34.9. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code M34.9?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) 7.02.02

Hematopoietic Cell Transplantation for Autoimmune Diseases and Miscellaneous Indications (CPB 0606, reviewed 2026-09-18)

Total Body Plethysmography (CPB 0474, reviewed 2026-07-17)

Hematopoietic Cell Transplantation for Autoimmune Diseases and Miscellaneous Indications (CPB 0606, reviewed 2025-09-10)

ADAMTS13 Assay for Thrombotic Thrombocytopenic Purpura (TTP) (CPB 0780, reviewed 2026-04-27)

Fetal Echocardiography and Magnetocardiography (CPB 0106, reviewed 2026-03-26)

What insurance policy changes affect code M34.9?

Which payers have updated policy for code M34.9?

How do I get notified when code M34.9 policy changes?

Why do payers change policies for code M34.9?